Two Latham Attorneys Recognized on List of Latin America’s Top 100 Female Lawyers
Latinvex names Marcela Ruenes and Katherine Sawyer to annual ranking.
Latham’s Washington, D.C. office offers clients powerhouse corporate capabilities, regulatory insights, as well as litigation and trial strength.
We have built a remarkable track record of navigating the federal government — in the courts, the White House and Executive Branch agencies, as well as Congress. As a group, we draw on experience serving in a wide variety of senior roles within the federal government, so we can advise clients based on deep knowledge of the inner workings of government.
We regularly represent clients facing criminal, civil, and congressional investigations, litigation in all US courts, and the full range of commercial disputes. Our courtroom victories regularly earn Latham recognition from National Law Journal as among the very best litigators and trial lawyers in Washington.
Unique among firms in the capital, we combine classic litigation and regulatory practices with our premier transactional practices, which include the largest and most successful corporate/M&A, capital markets, private equity, and leveraged finance practices in Washington.
As one of the world’s largest pro bono providers, Latham takes on matters in nearly every area of public interest law. In Washington, D.C., some of our key pro bono causes include advocating for asylum seekers, reuniting immigrant and refugee families, and safeguarding tenants’ rights, veterans’ rights, and civil rights.
Latinvex names Marcela Ruenes and Katherine Sawyer to annual ranking.
A team of Latham litigators secured a court order allowing Revolution Wind, the 80% complete, US$6.2 billion offshore wind project, to restart construction.
A Latham team led by David Frazier won the “Litigators of the Week” competition, alongside co-counsel at Covington, for their outstanding representation of AbbVie in securing the latest of five patent litigation settlements with generic makers that are set to protect its blockbuster immunology drug Rinvoq until 2037.